We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$5.41M
Cap. Flow
+$2.38M
Cap. Flow %
0.66%
Top 10 Hldgs %
7.17%
Holding
495
New
34
Increased
285
Reduced
131
Closed
45

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$2.11M
2
HSY icon
Hershey
HSY
+$2.09M
3
GILD icon
Gilead Sciences
GILD
+$2.07M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.05M
5
EIX icon
Edison International
EIX
+$2.04M

Top Sells

Rank Stock Value
1
HBAN icon
Huntington Bancshares
HBAN
+$2.13M
2
TKO icon
TKO Group
TKO
+$2.13M
3
WAT icon
Waters Corp
WAT
+$2.09M
4
STT icon
State Street
STT
+$2.07M
5
AON icon
Aon
AON
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 31.87%
2 Financials 20.97%
3 Technology 10.66%
4 Industrials 10.62%
5 Consumer Discretionary 7.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
276
Annexon
ANNX
$855M
$304K 0.08%
54,866
+1,339
+3% +$7.54K
PTGX icon
277
Protagonist Therapeutics
PTGX
$8.75B
$301K 0.08%
2,860
+70
+3% +$6.2K
APGE icon
278
Apogee Therapeutics
APGE
$10.2B
$298K 0.08%
3,538
+87
+3% +$6.32K
CELC icon
279
Celcuity
CELC
$4.03B
$296K 0.08%
2,589
+61
+2% +$6.65K
SMMT icon
280
Summit Therapeutics
SMMT
$10.6B
$294K 0.08%
15,519
+378
+2% +$6.11K
GHRS icon
281
GH Research
GHRS
$1.87B
$294K 0.08%
20,920
+512
+3% +$7.86K
BCAX
282
Bicara Therapeutics
BCAX
$1.78B
$293K 0.08%
14,755
+360
+3% +$6.2K
DNLI icon
283
Denali Therapeutics
DNLI
$3.67B
$291K 0.08%
15,166
+371
+3% +$7.38K
AMLX icon
284
Amylyx Pharmaceuticals
AMLX
$2.05B
$289K 0.08%
20,815
+508
+3% +$7.15K
MRCC
285
DELISTED
Monroe Capital Corp
MRCC
$288K 0.08%
62,628
-5,712
-8% -$33K
RCKT icon
286
Rocket Pharmaceuticals
RCKT
$348M
$288K 0.08%
80,438
+1,964
+3% +$7.81K
PGEN icon
287
Precigen
PGEN
$1.93B
$286K 0.08%
73,899
+1,804
+3% +$7.4K
SRRK icon
288
Scholar Rock
SRRK
$5.71B
$286K 0.08%
5,816
+140
+2% +$6.27K
MAIN icon
289
Main Street Capital
MAIN
$4.97B
$285K 0.08%
5,380
-951
-15% -$56.3K
OMER icon
290
Omeros
OMER
$709M
$284K 0.08%
26,865
+653
+2% +$7.7K
CYTK icon
291
Cytokinetics
CYTK
$11B
$284K 0.08%
4,303
+56
+1% +$3.56K
RAPP
292
Rapport Therapeutics
RAPP
$1.95B
$282K 0.08%
9,007
+218
+2% +$6.13K
CMPX icon
293
Compass Therapeutics
CMPX
$373M
$280K 0.08%
52,846
+1,290
+3% +$7.45K
GLUE icon
294
Monte Rosa Therapeutics
GLUE
$1.92B
$275K 0.08%
16,718
+408
+3% +$7.8K
STOK icon
295
Stoke Therapeutics
STOK
$1.82B
$274K 0.08%
8,418
+204
+2% +$6.69K
RCUS icon
296
Arcus Biosciences
RCUS
$3.57B
$274K 0.08%
12,664
+308
+2% +$6.65K
MBX
297
MBX Biosciences
MBX
$2.95B
$273K 0.08%
9,131
+221
+2% +$7.52K
ZYME icon
298
Zymeworks
ZYME
$1.68B
$268K 0.07%
10,702
+261
+2% +$6.17K
IRWD icon
299
Ironwood Pharmaceuticals
IRWD
$611M
$267K 0.07%
76,169
+1,858
+3% +$7.62K
IMTX icon
300
Immatics
IMTX
$1.24B
$267K 0.07%
27,159
+662
+2% +$6.49K
10 11
12
13 14

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
MA
Modus Advisors Excelsior, Minnesota $363M AUM 22.99% 1-Year Est. Return

Virtus Investment Advisers's Q1 2026 Portfolio in Review

As of Q1 2026, Virtus Investment Advisers held 495 positions worth $363M, down 1.5% from $368M the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.

Virtus Investment Advisers's Q1 2026 filing shows 34 new, 285 increased, 131 reduced and 45 closed positions. Its largest new stake was Hershey: 9,903 shares worth $2.06M. The largest sale was Huntington Bancshares, an estimated $2.13M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 27% a quarter earlier, followed by Financials and Technology.

  • Virtus Investment Advisers's largest Q1 2026 buy was Hershey: 9,903 shares worth $2.06M.
  • Virtus Investment Advisers added most to Amgen in Q1 2026, an estimated $2.11M increase.
  • Virtus Investment Advisers's biggest Q1 2026 reduction was Micron Technology, cutting an estimated $1.56M.
  • Virtus Investment Advisers fully exited Huntington Bancshares in Q1 2026, selling an estimated $2.13M.
  • Virtus Investment Advisers's ten largest holdings make up 7.2% of its $363M portfolio in Q1 2026.
  • Virtus Investment Advisers opened 34 new positions and closed 45 in Q1 2026.
  • Virtus Investment Advisers's portfolio value fell 1.5% quarter-over-quarter to $363M.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.